Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

PMID:
17947486
[PubMed - indexed for MEDLINE]
Free Article
2.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW.

Ann Oncol. 2010 Feb;21(2):376-81. doi: 10.1093/annonc/mdp292. Epub 2009 Jul 24.

PMID:
19633048
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB.

J Clin Oncol. 2007 Apr 10;25(11):1390-5. Erratum in: J Clin Oncol. 2007 Oct 10;25(29):4701.

PMID:
17416859
[PubMed - indexed for MEDLINE]
4.

Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, Meyers PA, Widemann BC, Tsokos M, Mackall CL.

J Clin Oncol. 2012 Nov 20;30(33):4141-7. doi: 10.1200/JCO.2012.44.1055. Epub 2012 Oct 15.

PMID:
23071222
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG.

J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.

PMID:
19652058
[PubMed - indexed for MEDLINE]
6.

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM.

Clin Cancer Res. 2008 Jun 1;14(11):3450-5. doi: 10.1158/1078-0432.CCR-07-1416.

PMID:
18519776
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS.

J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10.

PMID:
20458040
[PubMed - indexed for MEDLINE]
8.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S.

Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Erratum in: Clin Cancer Res. 2009 Nov 1;15(21):6744.

PMID:
19690193
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.

Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T.

Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41. doi: 10.1007/s00280-010-1544-1. Epub 2010 Dec 16.

PMID:
21161528
[PubMed - indexed for MEDLINE]
10.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
[PubMed - indexed for MEDLINE]
11.

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV.

Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21.

PMID:
19383817
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.

Clin Cancer Res. 2003 Nov 1;9(14):5195-204.

PMID:
14613999
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW.

Clin Cancer Res. 2001 Feb;7(2):231-42.

PMID:
11234874
[PubMed - indexed for MEDLINE]
Free Article
14.

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE.

Clin Cancer Res. 2010 Mar 15;16(6):1915-23. doi: 10.1158/1078-0432.CCR-09-2425. Epub 2010 Mar 2. Erratum in: Clin Cancer Res. 2010 Sep 15;16(18):4681. Dosage error in article text.

PMID:
20197484
[PubMed - indexed for MEDLINE]
Free Article
15.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW.

Ann Oncol. 2006 Feb;17(2):334-40. Epub 2005 Nov 10.

PMID:
16284058
[PubMed - indexed for MEDLINE]
Free Article
16.

Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.

Rosen LS, Brown J, Laxa B, Boulos L, Reiswig L, Henner WD, Lum RT, Schow SR, Maack CA, Keck JG, Mascavage JC, Dombroski JA, Gomez RF, Brown GL.

Clin Cancer Res. 2003 May;9(5):1628-38.

PMID:
12738715
[PubMed - indexed for MEDLINE]
Free Article
17.

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901.

PMID:
14676112
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

PMID:
14519631
[PubMed - indexed for MEDLINE]
Free Article
19.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK.

Clin Cancer Res. 2002 Jan;8(1):75-85.

PMID:
11801542
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK.

Invest New Drugs. 2012 Feb;30(1):316-26. doi: 10.1007/s10637-010-9535-y. Epub 2010 Sep 14.

PMID:
20839029
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk